Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder: An Observational Comparative Study
- 0334453088
Abstract
Introduction/ background: Overactive bladder (OAB) impairs quality of life, and antimuscarinic agents remain the mainstay of its drug treatment. Oxybutynin is non-selective and frequently causes anticholinergic adverse effects, whereas solifenacin is relatively M3-selective; local comparative data on their efficacy and tolerability are limited.
Objective: To compare the efficacy and adverse effects of solifenacin and oxybutynin in patients with overactive bladder (OAB).
Study Design and Setting: Prospective cohort study; Department of Physical Medicine and Rehabilitation, Armed Forces Institute of Rehabilitation Medicine (AFIRM), Rawalpindi, Pakistan, from July 2026 till September 2026 (ERC Case No. 01/2025).
Methodology: After ethical approval, 170 patients aged 18–65 years with OAB diagnosed by International Continence Society criteria and symptoms for ≥3 months were enrolled by non-probability consecutive sampling. Patients were grouped according to the drug prescribed by the treating physician in routine care: Group A (n=85) received solifenacin 5 mg once daily and Group B (n=85) received immediate-release oxybutynin 5 mg three times daily, for 3 months. Daytime frequency, urgency, nocturia and urge incontinence episodes (recorded in a voiding diary kept for three consecutive days before each assessment) and the OAB symptom severity score (0–12) were assessed at baseline and at 3 months; adverse effects were recorded at each follow-up visit (weeks 2, 4, 8 and 12). Data were analysed in SPSS v29.0. Change from baseline was compared between groups by independent-samples t-test, and adverse effects by chi-square or Fisher’s exact test; p≤0.05 was considered significant.
Results: The groups were comparable at baseline in age (42.3±11.4 vs 43.6±12.0 years), gender, BMI and duration of symptoms (all p>0.05). At 3 months, reductions from baseline were significantly greater with solifenacin than with oxybutynin for daytime frequency (33.0% vs 24.8%), urgency (54.9% vs 35.7%), nocturia (58.4% vs 37.9%), urge incontinence (66.8% vs 43.6%) and total OAB score (56.5% vs 38.7%) (all p≤0.002). Adverse effects were less frequent with solifenacin (24.7% vs 72.9%, p<0.001), including dry mouth (14.1% vs 44.7%), constipation (9.4% vs 34.1%), blurred vision (5.9% vs 25.9%), dizziness (4.7% vs 21.2%) and self-reported cognitive disturbance (2.4% vs 17.6%). Fewer patients discontinued treatment because of adverse effects with solifenacin (3.5% vs 16.5%, p=0.005).
Conclusion: In this single-centre cohort, solifenacin was associated with greater improvement in OAB symptoms and fewer adverse effects than immediate-release oxybutynin. Solifenacin may be considered in preference to immediate-release oxybutynin when an antimuscarinic is prescribed; randomised trials are needed to confirm these findings.
Metrics
License
Copyright (c) 2026 Muhammad Ammar Khan, Farooq Azam Rathore, Muhammad Zeeshan Nawaz, Waleed Latif, Aqsa Anwar, Danish Ali Mir

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.